Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

波士顿 - 市值1152.4亿美元的生物技术板块巨头Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)宣布,其用于治疗腰骶神经根病变 (LSR)疼痛的药物suzetrigine的二期研究达到了主要终点。研究显示疼痛强度有统计学意义的降低。然而,安慰剂组也显示出类似程度的降低,这引发了人们对该药物相对于安慰剂的有效性的质疑。根据 ...

Vertex Pharmaceuticals Inc.’s non-addictive drug helped patients with lower back pain, moving the company closer to selling ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but did not ...

This was the stock's second consecutive day of gains.

正如预期的那样，今年制药公司对并购仍有兴趣，但相较于大型并购，制药公司更倾向于小额交易。迄今为止宣布的最大额的一笔交易是Novo Holdings拟以165亿美元收购CDMO公司Catalent。

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.94% higher to $468.09 Monday, on what proved to be an all-around mixed ...

Jefferies分析师预测，Vertex的管线产品，特别是二期LSR疼痛和三期DPN疼痛治疗，将从2026年开始贡献50亿美元的新业务。正在进行的DPN疼痛三期试验尤为值得关注，预计将进入FDA审查和市场推出阶段。

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Stifel raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $494 from $490 and keeps a Hold rating on the shares. With shares up ...